- Report
- January 2026
- 246 Pages
Global
From €5195EUR$5,850USD£4,507GBP
- Report
- January 2026
- 159 Pages
Global
From €5195EUR$5,850USD£4,507GBP
- Report
- January 2026
- 587 Pages
Global
From €5195EUR$5,850USD£4,507GBP
- Report
- January 2026
- 382 Pages
Global
From €5195EUR$5,850USD£4,507GBP
- Report
- January 2026
- 173 Pages
Global
From €5195EUR$5,850USD£4,507GBP
- Report
- September 2025
- 144 Pages
Global
From €2663EUR$2,999USD£2,310GBP
- Report
- August 2025
- 150 Pages
Global
From €2663EUR$2,999USD£2,310GBP
- Report
- March 2025
- 142 Pages
Global
From €2663EUR$2,999USD£2,310GBP
- Report
- May 2025
- 120 Pages
Global
From €4218EUR$4,750USD£3,659GBP
- Report
- August 2025
- 145 Pages
Global
From €3508EUR$3,950USD£3,043GBP
- Report
- June 2025
- 140 Pages
Global
From €3508EUR$3,950USD£3,043GBP
- Report
- September 2025
- 150 Pages
Global
From €3419EUR$3,850USD£2,966GBP
€4307EUR$4,850USD£3,736GBP
- Report
- April 2025
- 150 Pages
Global
From €3419EUR$3,850USD£2,966GBP
€4307EUR$4,850USD£3,736GBP
- Report
- April 2025
- 150 Pages
Global
From €3419EUR$3,850USD£2,966GBP
€4307EUR$4,850USD£3,736GBP
- Report
- March 2025
- 150 Pages
Global
From €3419EUR$3,850USD£2,966GBP
€4307EUR$4,850USD£3,736GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2477EUR$2,789USD£2,149GBP
- Report
- December 2025
- 150 Pages
Global
From €3419EUR$3,850USD£2,966GBP
€4307EUR$4,850USD£3,736GBP
- Report
- May 2025
- 150 Pages
Global
From €3419EUR$3,850USD£2,966GBP
€4307EUR$4,850USD£3,736GBP
- Report
- April 2025
- 150 Pages
Global
From €3419EUR$3,850USD£2,966GBP
€4307EUR$4,850USD£3,736GBP
- Report
- May 2025
- 87 Pages
Global
From €3500EUR$4,222USD£3,142GBP

The Hospital Acquired Infection (HAI) market is a subset of the Infectious Diseases Drugs market. HAIs are infections that occur in a hospital setting, and can be caused by a variety of bacteria, viruses, and fungi. These infections can be difficult to treat, as they are often resistant to antibiotics. As such, HAI drugs are designed to target specific pathogens, and are often used in combination with other treatments.
The HAI market is driven by the increasing prevalence of antibiotic-resistant infections, as well as the need for more effective treatments. Additionally, the rising number of hospitalizations due to chronic illnesses has also contributed to the growth of the market.
Some of the major players in the HAI market include Merck & Co., Pfizer, GlaxoSmithKline, Sanofi, and Johnson & Johnson. These companies are actively developing new drugs and treatments to address the growing prevalence of HAIs. Show Less Read more